Sanjay Saxena, MD
Family Medicine · Hagerstown, MDNPI 1558428706
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,775 of the $59,618 with a category attached, or 65.0%. AbbVie accounts for 74.0% of it on its own, with 50 other manufacturers making up the rest. Reporting peaked in 2022 at $13,413 and has fallen 78.9% since, to $2,828 in 2025. Among family medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,236 payments — averaging $48.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$44K
- Lilly USA, LLC$2K
- Novo Nordisk$1K
- AstraZeneca$1K
- Amgen$1K
- Pfizer$971
- plus $9K from 45 others
What the payments were for
- Speaking & faculty fees$38,77565%
- Travel & lodging$1,4742%
- Food & beverage$19,26832%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$59,618 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 222 | $405,485 |
| XareltoRivaroxaban | 78 | $97,199 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $66,609 |
| EliquisApixaban | 37 | $53,608 |
| JanuviaSitagliptin Phosphate | 44 | $50,596 |
| OzempicSemaglutide | 29 | $48,511 |
| JanumetSitagliptin Phos/Metformin Hcl | 26 | $34,610 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $20,789 |
| JardianceEmpagliflozin | 14 | $18,382 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $17,577 |
| TrintellixVortioxetine Hydrobromide | 16 | $14,794 |
| LinzessLinaclotide | 18 | $12,034 |
| Oxymorphone Hcl ErOxymorphone Hcl | 13 | $11,476 |
| Dexlansoprazole DrDexlansoprazole | 19 | $7,070 |
| Atorvastatin Calcium | 538 | $6,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $2,111 | $405,485222 claims |
| Johnson & JohnsonXarelto | $491 | $97,19978 claims |
| MerckJanuvia, Janumet | $84 | $85,20770 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $723 | $84,18657 claims |
| PfizerEliquis | $971 | $53,60837 claims |
| Novo NordiskOzempic | $1,386 | $48,51129 claims |
| Boehringer IngelheimJardiance | $789 | $18,38214 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $413 | $14,79416 claims |
| AbbVieLinzess, Synthroid | $44,096 | $13,54558 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Hagerstown
- Tu BuiHagerstown$19K
- Preeti SaxenaHagerstown$18K
- Joseph AsuncionHagerstown$13K
- Judy WangHagerstown$12K
- Ghazala QadirHagerstown$12K
- Karen DonaldsonBaltimore$899K
- Louis JacquesBaltimore$522K
- Michael ObiefuneBaltimore$291K
- Thomas LawrenceBerlin$254K
- Casey ScottCambridge$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.